• By Concept
  • By Last Name
  • By Full Text

Harvard University

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.



Abnormal Hyperphosphorylation of Tau

Iqbal, Khalid

1 February 2001 - 30 April 2012
NATIONAL INSTITUTE ON AGING
Total Funding: $ 3,687,819

FY 2011
5R01AG019158-10
$ 298,576
FY 2010
5R01AG019158-09
$ 302,624
FY 2009
5R01AG019158-08
$ 430,357
FY 2008
5R01AG019158-07
$ 418,877
FY 2007
2R01AG019158-06A1
$ 416,053
FY 2006
5R01AG019158-05
$ 367,066
FY 2005
5R01AG019158-04
$ 370,796
FY 2004
5R01AG019158-03
$ 365,867
FY 2003
5R01AG019158-02
$ 361,103
FY 2002
1R01AG019158-01A1
$ 356,500
 
 
$ 3,687,819
Abstract

DESCRIPTION (provided by applicant): The overall objective of this proposal is to understand the molecular mechanism of neurofibrillary degeneration of abnormally hyperphosphorylated tau protein and, based on this knowledge, identify specific therapeutic targets for Alzheimer disease (AD), Down syndrome and other tauopathies which are characterized by this brain lesion. The activity of protein phosphatase (PP)-2A, which regulates phosphorylation of tau, is in turn regulated partly by its inhibitor I2PP2A. In a large percentage of neurons in AD brain, I2PP2A is translocated from its primary localization in the nucleus to the cytoplasm. As PP-2A and tau are localized in the cytoplasm, the increased cytoplasmic localization of I2PP2A in AD brain explains the inhibition of PP-2A, tau hyperphosphorylation and formation of neurofibrillary tangles. We propose (1) to investigate the molecular mechanism which controls the nuclear vs. cytoplasmic localization of I2PP2A in normal neurons. The transport factors (karyopherins) that mediate the import and export of I2PP2A into and out of the nuclei, and the I2PP2A domains which interact with these factors will be identified;(2) to elucidate the cause(s) of modified neuronal I2PP2A localization in Alzheimer's disease. We will investigate the effect of the cleavage of I2PP2A, which occurs in AD brains, on the I2PP2A interaction with the transport factors. We will also investigate the effects of the interactions of I2PP2A with other soluble and fixed proteins on I2PP2A localization in normal and AD brain, and the role of I2PP2A phosphorylation;(3) to generate transgenic mice which express the N-terminal half I2PP2A (observed in the cytoplasm of neurons in the AD brain) or a control variant of this protein localized in the nuclei, under the control of an inducible expression system. The effect of these transgenes on PP-2A activity, the activities of tau kinases regulated by PP-2A and abnormal hyperphosphorylation of tau, and as well as neurodegeneration and cognitive impairment, will be studied. These studies will lead to the elucidation of the mechanism of neurofibrillary degeneration and to the identification of one or more therapeutic targets. The studies will lead also to the generation of a cellular and an animal model of tauopathies, which can be used for the development of therapeutic drugs for diseases characterized by this lesion.

74 Resulting Publications

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.

Related Grants

Related Publications